Sotera Health (SHC)

• Market cap: $3.68B
• 1 day: 2.29%
• 5 days: -0.54%
• 1 month: -0.76%
• 3 months: -17.69%
• 6 months: -2.77%
• Year to date: -4.70%
• 1 year: -11.64%
• 5 years: -48.29%
• 10 years: -48.29%
• Sector: Healthcare
• Industry: Miscellaneous Health & Allied Services

About: Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three segments: Sterigenics, Nordion, and Nelson Labs. Sterigenics provides outsourced terminal sterilization and irradiation services for medical device, pharmaceutical, food safety, and advanced applications; Nordion provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process; and Nelson Labs provides outsourced microbiological and analytical chemistry testing for the medical device and pharmaceutical industries. Its geographical segments are the United States, Canada, Europe, and other regions.

Employees: 3,000

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

127% more repeat investments, than reductions

Existing positions increased: 100 | Existing positions reduced: 44

41% more capital invested

Capital invested by funds: $3.13B [Q2] → $4.42B (+$1.29B) [Q3]

38% more funds holding in top 10

Funds holding in top 10: 8 [Q2] → 11 (+3) [Q3]

10% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 29

0% more funds holding

Funds holding: 205 [Q2] → 206 (+1) [Q3]

0.21% more ownership

Funds ownership: 93.28% [Q2] → 93.49% (+0.21%) [Q3]

13% less call options, than puts

Call options by funds: $1.15M | Put options by funds: $1.33M

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $17 31% upside
• Avg. target: $18.50 43% upside
• High target: $20 54% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

RBC Capital Sean Dodge 48% 1-year accuracy 21 / 44 met price target	31% upside $17	Outperform Reiterated	21 Nov 2024
Citigroup Patrick Donnelly 47% 1-year accuracy 15 / 32 met price target	54% upside $20	Buy Maintained	6 Nov 2024